Abstract
CD22 is a B-cell specific membrane glycoprotein that mediates homotypic and heterotypic cell adhesion; it also regulates B-cell receptor (BCR)-mediated signals. Monoclonal antibodies (mAb) directed at the ligand binding domain of CD22 initiate CD22-mediated signal transduction and apoptosis in B-cell lymphomas (NHL). Amino acid analysis of the complimentary determining regions (CDRs) of six different anti-CD22 ligand blocking mAb revealed a high level of sequence conservation. The heavy chain CDRs 1, 2, and 3 are 85, 40, and 38% conserved, respectively; light chain CDRs 1, 2, and 3, are 95, 90 and 90% conserved, respectively. Based on these conserved sequences, five peptides were designed and synthesized. Only the sequence derived from heavy chain CDR2 (Peptide 5) demonstrated significant B-cell binding. Peptide 5 bound to both malignant and primary B-cells with very little T-cell binding. The affinity had a Km of 5 × 10−6 M. Peptide 5 mediated killing of several NHL cell lines to a degree similar to that of the parent mAb (HB22.7). Peptide 5’s loop structure was shown to be crucial for B-cell binding and ligand blocking. Mutational analysis revealed that most Peptide 5 amino acids were critical for B cell binding. Using a CD22 transfected COS cell line, we demonstrated CD22-specific binding and CD22 ligand blocking to a degree similar to HB22.7. Finally Peptide 5 was used as a vehicle to deliver a pro-apoptotic peptide into NHL cells. Peptide 5 was fused to a BH3 death domain-containing peptide which demonstrated more effective NHL cell killing than the parent peptide.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Al-Lazikani B, Lesk AM (1997) Chothia C: standard conformations for the canonical structures of immunoglobulins. J Mol Biol 273(4):927–948
Atherton E, Sheppard RC (1989) Solid phase peptide synthesis. IRL Press, Oxford
Doody GM, Justement LB, Delibrias CC, Matthews RJ, Lin J, Thomas ML, Fearon DT (1995) A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science 269(5221):242–244
Dorken B, Moldenhauer G, Pezzutto A, Schwartz R, Feller A, Kiesel S, Nadler LM (1986) HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol 136(12):4470–4479
Engel P, Nojima Y, Rothstein D, Zhou LJ, Wilson GL, Kehrl JH, Tedder TF (1993) The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils and monocytes. J Immunol 150:4719–4732
Engel P, Wagner N, Miller AS, Tedder TF (1995) Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. J Exp Med 181(4):1581–1586
Florence C, Florence R, Patrick M, Cedric B, Thierry C, Claude G, Jean-Claude M, Martinie P, Daniel P, Bernard P, Michael K, Roger L, Anthony R (2003) Biochemical. Biophys Res Commun 307:198–205
Gordon IL (1995) Scatchard analysis of fluorescent concanavalin. A binding to lymphocytes. Cytometry 20(3):238–244
Haas KM, Sen S, Sanford IG, Miller AS, Poe JC, Tedder TF (2006) CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J Immunol 177(5):3063–3073
Heap CJ, Wang Y, Pinheiro TJT, Reading SA, Jennings KR, Dimmock NJ (2005) Analysis of a17-amino acid residue, virus neutralizing microantibody. J Gen Virol 86:1791–1800
Hernandez J, Schoeder K, Blondelle SE, Pons FG, Lone YC, Simora A, Langlade-Demoyen P, Wilson DB, Zanetti M (2004) Antigenicity and immunogenicity of peptide analogues of a low affinity peptide of the human telomerase reverse transcriptase tumor antigen. Eur J Immunol 34(8):2331–2341
Kaiser E, Colescott RL, Bossinger CD, Cook PI (1970) Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem 34(2):595–598
Kelm S, Pelz A, Schauer R, Filbin MT, Tang S, de Bellard ME, Schnaar RL, Mahoney JA, Hartnell A, Bradfield P et al (1994) Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily. Curr Biol 4(11):965–972
King DS, Fields CG, Fields GB (1990) A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. Int J Pept Protein Res 36(3):255–266
Law CL, Craxton A, Otipoby KL, Sidorenko SP, Klaus SJ, Clark EC (1994) Regulation of signalling through B-lymphocyte antigen receptors by cell–cell interaction molecules. Immunol Today 15:442
Law CL, Aruffo A, Chandran KA, Doty RT, Clark EA (1995) Ig domains 1 and 2 of murine CD22 constitute the ligand-binding domain and bind multiple sialylated ligands expressed on B and T cells. J Immunol 155(7):3368–3376
Li R, Boehm AL, Miranda MB, Shangary S, Grandis JR, Johnson DE (2007) Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells. Neoplasia 9(10):801–811
Matthews RJ, Bowne DB, Flores E, Thomas ML (1992) Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences. Mol Cell Biol 12(5):2396–2405
Moreau C, Cartron PF, Hunt A, Meflah K, Green DR, Evan G, Vallette FM, Juin P (2003) Minimal BH3 peptides promote cell death by antagonizing anti-apoptotic proteins. J Biol Chem 278(21):19426–19435 Epub 2003 Mar
Plutzky J, Neel BG, Rosenberg RD, Eddy RL, Byers MG, Jani-Sait S, Shows TB (1992) Chromosomal localization of an SH2-containing tyrosine phosphatase (PTPN6). Genomics 13(3):869–872
Powell LD, Sgroi D, Sjoberg ER, Stamenkovic I, Varki A (1993) Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2, 6-linked sialic acids that are required for recognition. J Biol Chem 268(10):7019–7027
Privé GG, Melnick A (2006) Specific peptides for the therapeutic targeting of oncogenes. Curr Opin Genet Dev 16(1):71–77 Epub 2005
Qin W, Feng J, Zhou Lin Y-L, Shen B (2006) Fusion protein of CDR mimetic peptide with Fc inhibit TNF-alpha induced cytotoxicity. Mol Immunol 43(6):660–666
Sato S, Miller AS, Inaoki M, Bock CB, Jansen PJ, Tang ML, Tedder TF (1996) CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 5(6):551–562
Sato S, Tuscano JM, Inaoki M, Tedder TF (1998) CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin Immunol 10(4):287–297
Sgroi D, Varki A, Braesch-Andersen S, Stamenkovic I (1993) CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin. J Biol Chem 268(10):7011–7018
Sharabi A, Zinger H, Zborowsky M, Sthoeger ZM, Mozes E (2006) A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4 + CD25 + cells and TGF-beta. Proc Natl Acad Sci USA 103(23):8810–8815. Epub 2006 May
Shen SH, Bastien L, Posner BI, Chretien P (1991) A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases. Nature 352(6337):736–739
Siminovitch KA, Neel BG (1998) Regulation of B cell signal transduction by SH2-containing protein-tyrosine phosphatases. Semin Immunol 10(4):329–347
Stamenkovic I, Seed B (1990) The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion. Nature 345(6270):74–77
Stamenkovic I, Sgroi D, Aruffo A, Sy MS, Anderson T (1991) The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and alpha 2-6 sialyltransferase, CD75, on B cells. Cell 66(6):1133–1144
Stewart JM, Young JD (1984) Solid phase peptide synthesis. Pierce Chemical CO., Rockford
Takasaki W, Kajino Y, Kajino K, Murali R, Greene MI (1997) Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor. Nat Biotechnol 15(12):1266–1270
Tamir I, Dal Porto JM, Cambier JC (2000) Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2: regulators of B cell signal transduction. Curr Opin Immunol 12(3):307–315
Tedder TF, Tuscano J, Sato S, Kehrl JH (1997) CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 15:481–504
Tooze RM, Doody GM, Fearon DT (1997) Counterregulation by the coreceptors CD19 and CD22 of MAP kinase activation by membrane immunoglobulin. Immunity 7(1):59–67
Torres RM, Law CL, Santos-Argumedo L, Kirkham PA, Grabstein K, Parkhouse RM, Clark EA (1992) Identification and characterization of the murine homologue of CD22, a B lymphocyte-restricted adhesion molecule. J Immunol 149(8):2641–2649
Tuscano J, Engel P, Tedder TF, Kehrl JH (1996) Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation. Blood 87(11):4723–4730
Tuscano JM, Riva A, Toscano SN, Tedder TF, Kehrl JH (1999) CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood 94(4):1382–1392
Tuscano JM, O’Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL (2003) Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. Blood 101(9):3641–3647
Acknowledgements
This work was supported by the Leukemia and Lymphoma Society Translational Research Award, the Schwedler Foundation and DOD grant # 21262678.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pearson, D., O’Donnell, R.T., Cerejo, M. et al. CD22-Binding Peptides Derived from Anti-CD22 Ligand Blocking Antibodies Retain the Targeting and Cell Killing Properties of the Parent Antibodies and May Serve as a Drug Delivery Vehicle. Int J Pept Res Ther 14, 237–246 (2008). https://doi.org/10.1007/s10989-008-9138-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10989-008-9138-z